Grant: Team Grant: E-Rare Joint Transnational Call
University of Ottawa
$75,000.00
Recognition and Validation of Druggable Targets from the Response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks
FY 2018-19
Summary
Myotonic dystrophy type 1 (DM1) is the most common adult form of muscular dystrophy affects virtually all tissues; the untreatable condition causes significant illness and death impacting patient and family quality of life and socio-economic status. Limited physical activity and fatigue are main problems for individuals with DM1. Cognitive Behavioural Therapy (CBT) is a lifestyle intervention focused on the development of personal coping strategies that target solving current problems and changing unhelpful patterns in cognitions (e.g. thoughts, beliefs, and attitudes), behaviors, and emotional regulation. We have found CBT had a significant positive impact on fatigue, exercise capacity, and physical activity in DM1. It is not clear how CBT is helping, we are now going to use a wide array of scientific approaches to study blood cells from CBT treated DM1 patients to see if we can come to understand the mechanism of CBT improvement of DM1. We shall then see if there are drugs which might achieve this effect as well as looking for positive interactions with other experimental DM1 drugs, that is whether adding other drugs will help make the CBT effect even strpnger. This shall be done in patient cells as well as mice engineered to have DM1.
Department
Program
Team Grant: E-Rare Joint Transnational Call
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
387442
Name
Mackenzie Alexander E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Muscular Dystrophy Canada (Toronto, Ontario); Muscular Dystrophy Canada (Toronto, Ontario); MINISTRY OF EDUCATION, YOUTH AND SPORTS, Czech Republic (Prague); The French National Research Agency (France); The Netherlands Organization for Health Research and Development (ZonMw); Research Foundation - Flanders (Belgium)
Instname2
Genetics
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Recognition and Validation of Druggable Targets from the Response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$75,000
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Cognitive Behavioural Therapy (Cbt); Myotonic Dystrophy Type 1 (Dm1); Systems Biology
Abstract
Myotonic dystrophy type 1 (DM1) is the most common adult form of muscular dystrophy affects virtually all tissues; the untreatable condition causes significant illness and death impacting patient and family quality of life and socio-economic status. Limited physical activity and fatigue are main problems for individuals with DM1. Cognitive Behavioural Therapy (CBT) is a lifestyle intervention focused on the development of personal coping strategies that target solving current problems and changing unhelpful patterns in cognitions (e.g. thoughts, beliefs, and attitudes), behaviors, and emotional regulation. We have found CBT had a significant positive impact on fatigue, exercise capacity, and physical activity in DM1. It is not clear how CBT is helping, we are now going to use a wide array of scientific approaches to study blood cells from CBT treated DM1 patients to see if we can come to understand the mechanism of CBT improvement of DM1. We shall then see if there are drugs which might achieve this effect as well as looking for positive interactions with other experimental DM1 drugs, that is whether adding other drugs will help make the CBT effect even strpnger. This shall be done in patient cells as well as mice engineered to have DM1.
Competitiondate
201806
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mackenzie, Alexander E
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $75,000~ $0~